Credit Suisse analyst Tiago Fauth downgraded Prometheus (RXDX) to Neutral from Outperform with a $200 price target after Merck (MRK) announced plans to acquire the company for $10.8B in cash, or $200 per share.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXDX: